Autologous CD19/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease.

IF 13.3 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2026-04-10 DOI:10.1016/j.medj.2026.101036

Henry J Kaminski, Linda L Kusner

引用次数: 0

Abstract

Ruan and colleagues report that dual-target CD19/BCMA CAR-T cell therapy produced marked clinical improvement in highly refractory myasthenia gravis, with steroid discontinuation and minimal toxicity. Beyond symptom control, deep immune profiling revealed sustained B-cell depletion, reduced autoantibodies, and systemic immune reprogramming toward a less inflammatory state.

查看原文本刊更多论文

自体CD19/BCMA CAR-T细胞治疗重症肌无力：推进重症患者的护理

阮和他的同事报告说，双靶点CD19/BCMA CAR-T细胞治疗对高度难治性重症肌无力产生了显著的临床改善，类固醇停药和毒性很小。除了症状控制之外，深度免疫分析显示持续的b细胞耗竭，自身抗体减少，以及系统性免疫重编程，以减少炎症状态。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.